Bloomage Houyuan Biotechnology (Hainan) Co., Ltd. was signed as a key Sino-Japanese green and low-carbon cooperation project in China-Japan Energy Conservation and Environmental Protection Forum.

2023.02.15

As a green and low-carbon technology, biotechnology has played an increasingly important role in assisting the dual-carbon goal and global sustainable development in recent years due to its advantages of energy-saving, consumption reduction, and efficiency enhancement.

On February 11th, the 16th China-Japan Energy Conservation and Environmental Protection Forum was held in Beijing. The joint venture company Bloomage Houyuan Biotechnology (Hainan) Co., Ltd., which is jointly invested by Bloomage Biotechnology (Hainan) Co., a subsidiary of Bloomage Biotech, Japan's Rohto Pharmaceutical Co., Ltd. ("Rohto Pharma") and BioMimetics Sympathies ("BMS"), made its appearance at this forum. The company was signed as a key Sino-Japanese green and low-carbon cooperation project in the forum.

With a strong focus on the expanding field of biomedical research and high expectations for the prospects of China's regenerative medicine development, Bloomage Houyuan will introduce the leading AOF mesenchymal stem cell culture technology from Japan. They will launch a series of regenerative medicine products and customized development services, including BloomStem series AOF mesenchymal stem cell Expansion culture medium, various high-performance cell culture medium, and cell culture derivatives, dedicated to providing cutting-edge high-performance products and high-quality customized services for biomedical enterprises, medical institutions, and research units.